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Resveratrol, a natural phytoalexin found in grapes and red wine, displays anti-cancer 
activities through a variety of mechanisms that include the induction of cancer cell 
apoptosis. Although high concentrations may be needed for the efficacy of resveratrol 
alone, the compound shows promise as a potent sensitizer of the apoptotic effect of 
other anti-cancer agents, including death ligand TRAIL. Intracellular heat shock 
proteins (Hsps) are frequently up-regulated in cancer cells, conferring resistance to 
apoptosis. Modulation of these proteins may overcome the resistance and increase 
efficacy of anticancer therapies. 
 
 In this study, resveratrol caused significant dose-dependent apoptosis or necrosis in the 
lymphoid and myeloid leukaemia cell lines Jurkat and U937 at 50µM and above. 
Combination treatments with sub-lethal concentrations of ethanol or TRAIL showed 
synergistic effects on the dose-dependent cell death, such that significant apoptosis was 
achieved at 25µM resveratrol. Treatment with all compounds together showed the 
greatest efficacy with significant apoptosis occurring at 12.5µM resveratrol, but also 
greater toxicity demonstrated by a shift from apoptosis to necrosis occurring at 25-
50µM as opposed to 100-200µM resveratrol in the other combination treatments.  
 
Low concentrations of resveratrol that were unable to induce apoptosis caused a 
significant increase in intracellular Hsp72, whilst intracellular Hsp72 was unchanged or 
reduced at higher concentrations. Increasing intracellular Hsp72 expression in cells 
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with a mild heat shock prior to resveratrol treatment caused increased resistance to 
resveratrol-induced cell death at 50-200µM. It was not possible to show that lowering 
intracellular Hsp72 with ethanol treatment increased sensitivity to resveratrol-induced 
cell death. It was shown for the first time that resveratrol increased surface expression 
of Hsp72 at all concentrations, highlighting the potential for an additional anti-cancer 
effect in situ.  
 
The results indicate that combination treatments with resveratrol are promising for use 
in anticancer therapy, and manipulation of intracellular Hsp72 expression may 
modulate the efficacy of resveratrol-induced apoptosis. Further investigations are 
recommended into the clinical relevance of resveratrol, further synergistic compounds, 
and the effects of reducing intracellular and increasing surface Hsp72 levels.  
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1.1. Resveratrol and its health-beneficial properties 
 
Resveratrol (3,5,4’-hydroxystilbene) is a polyphenolic compound produced in a 
number of plant species in response to stress. It protects plants by blocking the 
proliferation of pathogens (Delmas et al., 2006). Resveratrol is thought to be 
particularly abundant in grapes and wine, and is also found in mulberries, cranberries, 
peanuts, and plants of the Cassia quinquangulata family (Gescher and Steward, 2003). 
As a constituent of grape skin, its concentration reaches 10–20mM in red wine (Manna 
et al, 2000). Resveratrol is believed to be found in sufficiently high concentrations in 
dietary components to provide a potential impact on human health (Baur and Sinclair, 
2006). Both trans and cis isomers of resveratrol exist, but as the trans isomer is much 
more common it is this form that is most commonly considered, and referred to 
throughout this paper (Signorelli and Ghidoni, 2005).  
 
Efforts to identify dietary compounds with health-promoting activity intensified when 
the link between diet and pathogenesis was established (Hsieh et al, 2008). Interest in 
resveratrol has increased concomitantly with the discoveries of many pronounced 
pharmacological effects displayed in different experimental models. A strong 
collection of evidence from a large number of epidemiological, animal and in vitro 
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studies suggests that resveratrol exhibits a wide range of beneficial effects for health 
(Bernhard et al., 2000).  
 
Resveratrol has been shown to be protective at the cellular level against various 
toxicities and neurodamage, and in a larger/systemic context against cancer, 
cardiovascular disease and age-related neurogenerative disorders (Han et al., 2006). It 
has been widely hypothesised that resveratrol plays an important part in the reported 
benefits of wine consumption and reduced mortality from cardiovascular disease 
observed in the French paradox1. This hypothesis is based on research demonstrating 
that resveratrol is a powerful antioxidant and anti-inflammatory agent, prevents platelet 
aggregation and coagulation, modulates arachidonic acid metabolism, lipid metabolism 
and prevents LDL oxidation (Bernhard et al., 2000).  
 
In 1997, resveratrol was also shown to be an effective anti-cancer agent in all stages of 
carcinogenesis (Jang et al., 1997), and this propelled the interest in the compound as a 
chemopreventive and chemotherapeutic agent. Its protective effects by preventing 
aberration of normal cells have now been well established; however, resveratrol has 
also been shown to be cytotoxic towards transformed cells (Delmas et al., 2006). Thus, 
the effects of resveratrol vary between pro-survival and pro-death mechanisms, 
seemingly dependent on what is required to promote the health of the particular tissue 
(Signorelli and Ghidoni, 2005).  
                                                 
1 The French paradox is the observation that cardiovascular disease is reported as cause of death in 
relatively lower numbers in the French compared with other Western populations, despite the French 
diet being high in saturated fats, a known contributing factor to cardiovascular disease.  Their diets are 
also reported to comprise relatively high levels of red wine. 
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Resveratrol is a lipophilic compound that can cross the plasma membrane of cells, and 
has been shown to enter cells via passive diffusion as well as carrier-mediated transport 
(Lançon et al., 2004). Resveratrol also acts at the membrane, binding to specific 
receptors, e.g. the oestrogen, insulin-like growth factor-1 and epidermal growth factor 
receptors, and various other membrane sites (Han et al., 2006). Research is being 
conducted to elucidate specific protein targets for resveratrol. It has been observed to 
interact with several targets on the cell membrane and intracellular environment, which 
have been termed resveratrol-targeting proteins (RTPs; Hsieh et al., 2008).  
 
The various beneficial effects of resveratrol are attributed not only to its powerful 
antioxidant nature, but more importantly to this ability to interact with a wide range of 
cellular targets and thus, modulate various signal transduction pathways (Han et al., 
2006). For example, resveratrol may protect against toxicity in hippocampal cells by 
rapidly activating the protein kinase C pathway (Han et al., 2004) and induce apoptosis 
of various tumour cell lines by inhibiting the PI3 kinase/AKT or MAPK pathways 
(Aziz et al., 2006; Fulda and Debtain, 2006). The diversity of effects displayed are 
thought to be dependent on cell type, cellular condition, molecular setting and 
concentration of resveratrol (Hsieh et al., 2008; Signorelli and Ghidoni, 2005). Hsieh et 
al. (2008) suggest that the diverse effects and broad concentration-dependence of 
resveratrol may be explained by qualitative and quantitative differences in type and 
level of RTPs in different cells. Many different molecular mechanisms displayed by 
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resveratrol have been reported, but further research is still required to determine 
mechanisms displayed in different cellular and molecular settings.  
 
1.2. Anti-cancer properties of resveratrol 
 
Jang et al. (1997) first highlighted the promising anti-cancer properties of resveratrol 
by demonstrating its activity against all three stages of carcinogenesis: initiation, 
promotion and progression. They demonstrated that resveratrol is able to inhibit 
initiation and promotion of hydrocarbon-induced skin cancer and the progression of 
breast cancer in mice. Further research continues to show promising roles for 
resveratrol in more advanced stages of cancer, most recently as a possible compound to 
enhance the efficacy of the body’s natural defences and anti-cancer drugs (Delmas et 
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Figure 1.1. Resveratrol displays a variety of anti-cancer mechanisms which are chemopreventive, 
chemotherapeutic, or both. Adapted from Kundu and Surh (2008). 
 
As illustrated in figure 1.1, resveratrol may exert its anti-cancer activities through 
different mechanisms that may be classed as chemoprevention, chemotherapy or 
encompass both.  
• A major chemopreventive effect results from the ability of resveratrol to modulate 
phase I and II enzymes which are involved both in the activation and detoxification 
of carcinogens. Resveratrol has been shown to inhibit phase I enzymes in the 
metabolism of xenobiotics, thus preventing activation of carcinogenic forms of 
chemicals. In addition, resveratrol has been shown to induce phase II 
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antioxidant/detoxification enzymes, thereby speeding up the excretion of 
potentially carcinogenic agents and boosting antioxidant activity (Signorelli and 
Ghidoni, 2005; Kundu and Surh, 2008).  
• Another chemopreventive effect results from the ability of resveratrol to modulate 
regulatory proteins of the cell cycle, thus causing cell cycle arrest and inhibition of 
abnormal proliferation. Several studies have shown that resveratrol causes growth 
arrest of different tumour cell lines at different stages of the cell cycle. The growth 
arrest may be irreversible and progress to apoptosis (Signorelli and Ghidoni, 2005). 
• Resveratrol has been shown to modulate mediators of inflammation e.g. 
cyclooxygenase-2 (COX-2) and nitric oxide (NO) which are involved in promotion 
and progression of cancers by stimulating cell growth and migration (Kundu and 
Surh, 2008). Thus, the anti-inflammatory properties of resveratrol contribute to its 
chemo-preventive and -therapeutic effects.  
• Resveratrol is a selective modulator of oestrogen receptor activity, a property that 
may prevent tumour initiation, promotion and progression of hormone-dependent 
tumours (e.g. breast, prostate, lung and colon; Signorelli and Ghidoni, 2005).  
• Resveratrol has been shown to induce apoptosis in several different tumour cells in 
vitro as well as in chemically induced and transplanted tumours in mice (Garvin et 
al., 2006; Kalra et al., 2008; Clément et al., 1998; Bernhard et al., 2000; Dörrie et 
al., 2001; Delmas et al., 2003). Several different apoptotic mechanisms of 
resveratrol have been reported within both the extrinsic and intrinsic apoptotic 
pathways, and may vary between different cell types. A large collection of 
evidence suggests that resveratrol-induced apoptosis is linked to its ability to:  
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– modulate anti- and pro-apoptotic proteins and pathways. For example, 
resveratrol has been shown to deplete ‘inhibitor of apoptosis proteins’, e.g. 
survivin (Hayashibara et al., 2002). High levels of survivin have been found 
expressed in the majority of human cancers, and depletion of survivin by 
resveratrol has been found to sensitise such cells to apoptosis. Resveratrol 
also modulates intracellular signalling pathways involved in apoptosis, e.g. 
by inhibiting the anti-apoptotic PI3K/AKT and MAPK pathways in several 
tumour cell lines (Fulda and Debatin, 2006). 
– regulate gene expression of proteins involved in apoptosis, e.g. by 
modulating transcription factors, inhibiting NFκβ pathways and 
upregulating p53-responsive genes (Fulda and Debatin, 2006) 
– activate death receptor signalling on the cell surface, e.g. CD95-CD95L 
signalling (Clément et al, 1998), by redistributing death receptors on the 
cell membrane sensitising cells to apoptosis (Delmas et al., 2004) 
– modulate several other cellular mechanisms, e.g. sphingolipid signalling 
and drug transporters causing tumour cells to become sensitised to 
apoptosis (Signorelli and Ghidoni, 2005) 
• Resveratrol has been shown to suppress invasion, metastasis and angiogenesis of 
tumours by inhibiting multiple proteins and signalling cascades involved in these 
processes (Kundu and Surh, 2008). For example, resveratrol has been shown to 
inhibit VEGF-induced angiogenesis (Lin et al, 2003). Resveratrol has also been 
shown to sensitise tumour cells to apoptosis induced by death receptors and 
anticancer drugs and therapies (Fulda and Debatin, 2004; Sun et al., 2002; Kubota 
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et al., 2003; Jazirehi and Bonavida, 2004; Zoberi et al., 2002; Fulda and Debatin, 
2005; Delmas et al., 2004).   
• For comprehensive reviews on the mechanisms behind resveratrol’s anti-cancer 
effects see Kundu and Surh (2008), Signorelli and Ghidoni (2005) and Fulda and 
Debatin (2006).  
 
 
1.2.1. Resveratrol-induced apoptosis in anti-cancer therapy 
 
Despite advances in anti-cancer therapies, resistance of tumour cells to treatment and 
relapse of the disease have proved to be major setbacks to survival rates of sufferers. 
Certain leukaemias have proved particularly resistant to anticancer therapy 
demonstrating the need for new and more effective treatments (Cecchinato et al., 
2007). Resveratrol has been suggested to be a promising anti-leukemic agent (Gautam 
et al., 2000). Several studies have demonstrated the anti-proliferative and apoptotic 
effect of resveratrol in various myeloid (U937, HL60, THP-1, KCL22, and K562) and 
lymphoid (Jurkat and WSU-CLL) leukaemia cell lines (Clément et al., 1998; Ferry-
Dumazet et al., 2002; Park et al., 2001; Su et al., 2005; Dörrie et al., 2001; Manna et 
al., 2000). 
 
Pathways involved in resveratrol-induced cell death have been characterised in 
leukaemia cells previously. Apoptosis through the Fas-FasL pathway has been 
demonstrated (Clément et al., 1998) as well as through the Fas-independent, 
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mitochondria/caspase-9 pathway in cells that are resistant to Fas signaling (Dörrie et 
al., 2001). Su et al. (2005) demonstrated that in HL-60 cells resveratrol induced 
apoptosis through the Cdc42/apoptosis signal-regulating kinase 1/c-Jun N-terminal 
kinase/FasL signaling cascade. Resveratrol has also been observed to down-regulate 
anti-apoptotic proteins (e.g. survivin, iNOS and Bcl-2; Fulda and Debatin, 2005; Athar 
et al., 2007) and significantly suppress interleukin activation of nuclear factor kappa-β 
(NFκB; Athar et al., 2007) in leukaemia cells in vitro. Manna et al. (2000) observed 
that resveratrol caused suppression of NFκB induction by inhibiting activation of 
mitogen-activated protein kinase (MAPK) kinase and c-Jun terminal kinase in Jurkat, 
U937, HeLa and H4 cells, and that resveratrol abrogated TNF-α cytotoxicity. It has 
also been proposed that resveratrol increases susceptibility of K562 leukaemia cells to 
apoptosis by interfering with Hsp70 expression (Chakraborty et al., 2008).  
 
Whilst the protective anti-inflammatory and anti-proliferative effects of resveratrol are 
believed to affect normal and transformed cells, the apoptotic effect of resveratrol has 
been highlighted as promising for anticancer therapy by potentially being cancer cell 
specific (Signorelli and Ghidoni, 2005). Several studies have reported that resveratrol 
causes apoptosis of cancer cells whilst being non-toxic to equivalent normal cells. 
Clément et al. (1998) reported that 16-32µM resveratrol induced apoptosis in HL60 
human leukaemia cells after 24 hours treatment, but up to 72 hours incubation with the 
same concentrations showed minimal toxicity to peripheral blood lymphocytes (PBLs). 
Similarly, Dörrie et al. (2001) reported that resveratrol caused ≥80% cell death of 
several leukaemia cell lines whilst no significant toxicity on peripheral blood 
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mononuclear cells was detected. Gautam et al. (2000) reported resveratrol-induced 
apoptosis of human leukaemia cell lines U937 and HL-60, but no apoptotic effect on 
normal hematopoietic progenitor cells. Resveratrol has also been shown to induce 
apopotis of human prostate cancer cells (LNCaP) whilst not affecting normal prostate 
epithelial cells (Aziz et al., 2006).   
 
However, despite several studies suggesting that the apoptotic effect of resveratrol is 
cancer cell specific, Ferry-Dumazet et al. (2002) reported a general toxicity of 
resveratrol on normal and leukeamic haematopoietic cells. The team studied the 
toxicity of resveratrol on several different haematopoietic cells and confirmed previous 
reports of minimal toxicity to inactivated PBLs, but reported resveratrol-induced 
apoptosis of several other normal cycling haematopoietic cells. They suggested that 
this toxicity makes resveratrol inappropriate for use as a primary anti-leukaemic agent 
(Ferry-Dumazet et al., 2002).  
 
Different cell types vary in sensitivity and pharmacological outcome to resveratrol. 
Whilst nanomolar concentrations may be effective in some cells, higher concentrations 
are required for efficacy in other cells (Signorelli and Ghidoni, 2005). Since relatively 
high concentrations of resveratrol may be required for efficacy and toxicity to normal 
cells has been reported, resveratrol may have greater value combined with other 
anticancer therapies. Low concentrations of resveratrol have proved highly effective at 
sensitising various tumour cells to apoptosis induced by death ligands and anticancer 
drugs (Fulda and Debatin, 2004; Fulda and Debatin, 2005; Delmas et al., 2004; Sun et 
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al., 2002; Kubota et al., 2003; Jazirehi and Bonavida, 2004). Synergistic combination 
treatments may enhance cancer cell death and reduce toxicity and undesirable side 







Apoptosis is often disregulated in disease. Hyperproliferation and cancer results when 
apoptosis is prevented, whereas excessive apoptosis causes tissue damage/loss in 
ischemic diseases and neurodegenerative disorders (Fulda and Debatin, 2006). Cancer 
cells persist by continuing to evade the normal process of apoptosis. This requires 
deregulation of several proteins involved in cell survival, e.g. inhibition of pro-
apoptotic proteins and activation of anti-apoptotic/survival proteins.  
 
Most cytotoxic cancer therapies operate by stimulating apoptosis (Fulda and Debatin, 
2006; Johnstone et al., 2002). Thus, their efficacy depends on the ability to target 
functional apoptotic pathways. However, many tumours prove resistant to treatment, 
even when aggressive, due to the deregulation of apoptotic signalling pathways (Fulda 
and Debatin, 2006). This is most deeply featured in advanced cancer cells and reduces 
or prevents drug efficacy. Methods to enhance the apoptotic effect of anti-cancer 
agents are required to target tumour resistance and develop more effective treatments.  
 
Apoptosis is a highly regulated and characteristic process of cell death essential for 
tissue homeostasis (Moulin & Arrigo, 2006). The process involves a caspase cascade in 
which activator caspases activate effector caspases, which fragment cellular 
components and cause internal cellular destruction. Apoptosis can occur via two 
pathways: 1) the intrinsic pathway in which intracellular stress signals target the 
mitochondria and cause release of cytochrome c, and 2) the extrinsic pathway in which 
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death receptors are activated by ligation on the cell surface and form a death-inducing 
signalling complex (DISC). The activator caspase in the intrinsic pathway, caspase-9, 
is formed upon cytochrome c release from stressed mitochondria and the formation of 
an apoptosome complex leading to caspase-3 activation (Fulda and Debatin, 2005). In 
the extrinsic pathway, death receptor stimulation results in the recruitment of an 
adaptor molecule (e.g. Fas-associated death domain [FADD]) and the formation of the 
DISC activates caspase-8 (Fulda and Debatin, 2005; Clemons and Anderson, 2006). 
Cross talk exists between the two pathways, and extrinsic death signals can lead to 
activation of the intrinsic pathway via members of the Bcl-2 family which cause 
release of cytochrome c upon cleavage by caspase-8 (Fulda and Debatin, 2005).  
 
It is believed that death receptor ligands bind to pre-associated trimers of their 
receptors (Delmas et al., 2004) and that two ligands bound to a hexameric receptor 
complex is required to induce apoptosis. Strong DISC formation and more efficient 
apoptosis signalling is believed to result from the clustering of multiple receptor 
trimers within membrane microdomains (lipid rafts). 
 
Death receptors are members of the tumour necrosis factor (TNF) receptor 
superfamily, and include TNF-α, CD95 (APO-1/Fas) and TNF-related apoptosis-
inducing ligand (TRAIL; Fulda and Debatin, 2006; Clemons and Anderson, 2006). 
TRAIL binds to death receptors DR4 and DR5 to induce apoptosis, but may also bind 
to decoy receptors DcR1 and DcR2 which do not stimulate apoptosis. TRAIL is a 
promising agent for anti-cancer therapy because it has been shown to induce apoptosis 
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specifically of cancer cells and display little toxicity (Psahoulia et al., 2007). Whilst 
systemic toxicity after administration of other death ligands (CD95L and TNFα) has 
been reported, administration of TRAIL has not produced such toxicity in mice or non-
human primates (Fulda and Debatin, 2005). Unfortunately, cancer cells can also 
display resistance to TRAIL-induced apoptosis, possibly due to expression of decoy 




1.4. Heat Shock Proteins 
 
Altered heat shock protein (Hsp) expression has been reported in a wide range of 
tumour cells and over-expression is believed to confer resistance to apoptosis (Jolly 
and Morimoto, 2000). Over-expression of Hsps is a common feature of cancer cells 
and has been associated with resistance to therapy and poor prognosis of the sufferers 
(Clemons and Anderson, 2006; Lanneau et al., 2008).  
 
Hsps are a highly conserved class of proteins that act as molecular chaperones and 
proteases within the cell and are expressed at elevated levels in response to stress to 
counteract toxicity and cell death. They serve essential maintenance and protective 
roles under normal conditions (Garrido et al., 2001; Multhoff, 2007). Under stress, 
their roles are expanded and Hsps include anti- and pro-apoptotic proteins that act at 
various points in the apoptosis pathways. “Their expression level can determine the 
fate of a cell in response to a death stimulus” (Garrido et al., 2001). Hsps are induced 
by most forms of cellular stress. Their induction is often referred to as a heat shock 
response or stress response. There are six major families of Hsps, traditionally named 
after their molecular size: Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and small Hsps (Jolly 
and Moriomoto, 2000). Kampinga et al. (2009) have recently proposed new guidelines 
for the nomenclature of human Hsps. Although this paper will use the traditional 
nomenclature, the author realises the value of using the new nomenclature in future 
work.  
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1.4.1. Induction of Hsp expression 
 
Each Hsp family includes members with constitutive or inducible expression, and that 
reside in different cellular compartments. Expression of inducible proteins is quickly 
up-regulated by appropriate stress or apoptotic stimuli (Sõti et al., 2005). The induction 
occurs when heat shock factor (HSF)-1 is activated and translocates to the nucleus to 
act as a transcription factor. Under normal conditions it is maintained inactive by the 
binding of Hsps, which dissociate from and activate HSF-1 when they become 
occupied by increases in damaged proteins (Sõti et al., 2005). However, Hsps are 
present at abnormal levels in many disease states, including several cancer cell types, 
without any evidence existing for increased levels of damaged proteins to explain the 
effect. Certain compounds, e.g. curcumin, will induce a heat shock response in 
transformed cells but not normal cells (Khar et al., 2001). It is now known that 
different types of stresses can induce different expression patterns of Hsps, suggesting 
that several mechanisms to regulate Hsps expression exist (Sõti et al., 2005). Thus, not 
only increased levels of damaged proteins are able to induce Hsp expression and 
alternative signals for induction have been proposed.  
 
There is growing interest in the concept that the cell membrane acts as a sensor for 
stress and can induce Hsps expression. It has been shown that stress-induced 
membrane alterations transmit signals to induce Hsp expression (Carratù et al., 1996; 
Horváth et al., 1998; Vigh et al., 2007). Stress-induced alterations include changes in 
membrane fluidity and composition, which often relate to changes in membrane 
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microdomains termed ‘lipid rafts’. There is mounting evidence that hyperfluidization 
of the cell membrane induces the Hsp response as a result of reorganisation of the lipid 
rafts (Balogh et al., 2005; Nagy et al., 2007; Vigh et al., 2007) suggesting that agents 
that cause such membrane alterations may induce the heat shock response. 
 
 
1.4.2. Hsps and apoptosis  
 
Hsps have been found to play an important protective role against apoptosis by 
interfering with caspase activation. Either of Hsp27, Hsp60, Hsp70, and Hsp90 have 
been found to inhibit caspase activation and prevent apoptosis when over-expressed, 
and increase cellular sensitivity to apoptotic stimuli when depleted (Lanneau et al., 
2008). Hsp27 and Hsp70 are believed to be more strongly anti-apoptotic and are 
implicated in carcinogenesis. Elevated cytosolic levels of these proteins have been 
shown to increase the tumorigenic potential of rodent cells in experimental models 
(Garrido et al., 2001).  
 
The Hsp70 family is the best studied class of Hsps and the most conserved. It 
comprises at least 11 genes in humans, including the constitutively expressed Hsc70 
and the inducible Hsp72 that are mainly found in the cytosol, the mitochondrial 
mtHsp70 and the endoplasmic reticulum-localised Grp78 (Lanneau et al., 2008). Hsp72 
is believed to be one of the most powerful anti-apoptotic proteins by being able to 
block almost all identified cell death pathways. High expression of Hsp70 alone has 
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been shown to prevent apoptosis from being induced by a variety of stresses (Clemons 
and Anderson, 2006), whereas elimination of Hsp70 expression with antisense 
oligonucleotides has been shown to result in apoptosis and cell growth arrest of cancer 
cells (Jolly and Morimoto, 2000).  
 
 
1.4.3. Dual role of Hsps 
 
In recent years, there has been growing evidence of a dual role of Hsps. Whilst 
exhibiting strong cytoprotective properties in the intracellular environment, membrane-
bound and extracellular Hsps have been shown to display immunogenic properties to 
the extent that Hsp70 expression at the plasma membrane can facilitates elimination of 
tumour cells by the immune system (Multhoff, 2007). Particularly members of the 
Hsp70 and Hsp90 families have been observed in the extracellular environment. Hsp70 
has been shown to be frequently present on the plasma membrane of several cancer 
cells including leukemia cells, with no membrane localisation of Hsp70 being found in 
the corresponding normal tissues (Schmitt et al, 2007). 
 
Elevated levels of Hsp70 and Hsp90 have been detected in the medium of tumour cell 
lines and in antigen presenting cells, as well as in the serum of cancer patients (Schmitt 
et al., 2007; Mutlhoff, 2007). Serum levels may be the result of proteins expelled in 
apoptosis and necrosis. However, this mechanism is unlikely to account for the 
magnitude detected and there is increasing evidence for an active secretion process of 
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Hsps from viable tumour cells, despite Hsps not containing leader peptides. Several 
research groups have observed active release of Hsp70 from the cytosol to the plasma 
membrane. It has been suggested that Hsp70 release may occur via a non-classical 
protein secretion pathway involving lipid rafts (Hunter-Lavin et al., 2004), and active 
release from viable tumour cells via exosomes has been reported by Gastpar et al. 
(2005). Stress stimuli have shown to be capable of increasing active release of Hsp70 
from these cells (Schmitt et al., 2007).  
 
The immunogenic roles of extracellular Hsps have been shown to be varied and play an 
important part in modulating the innate and adaptive immune responses, with the roles 
of Hsp70 being the best studied. Different functions of Hsp70 include stimulating the 
release of chemokines, proinflammatory cytokines and nitric oxide, facilitating 
receptor-mediated endocytosis and processing and presenting peptides on MHC class I 
molecules (Schmitt et al., 2007). Tumour cells that present Hsp70 on the cell surface 
have been shown to stimulate activation by natural killer (NK) cells. (Schmitt et al., 
2007). 
 
Treatment of cells with various reagents/treatments e.g. hyperthermia has been shown 
to increase the expression of membrane-bound Hsp70 on the surface of tumour cells 
and thus, increase sensitivity to NK cell-mediated killing. The effect was tumour cell-
specific for some treatments (Gehrmann et al., 2002). Gehrmann et al. (2004) 
demonstrated this effect using anti-inflammatory drugs including inhibitory agents of 
COX1/2, and suggested that the effect is a biological rational for combining such drugs 
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with immunotherapy in cancer therapy. Resveratrol is an anti-inflammatory inhibitor of 
COX1/2 and thus may stimulate a similar effect. 
 
 
1.4.4. Hsps and resveratrol in anti-cancer therapy 
 
Due to the important localisation-dependent roles of Hsps in tumour cell survival, 
agents that block the intracellular and enhance the extracellular functions of Hsps are 
believed to be of benefit in anticancer therapy. Either method has shown promising 
effects on tumour suppression. However, it has been proposed that both effects in 
combination would be most effective (Scmitt et al., 2007).  
 
There are various and contradictory reports of the effect of resveratrol on Hsp70 
expression in cancer cells. Chakraborty et al. (2008) reported that 40µM resveratrol 
induced apoptosis in myelogenous leukaemia K562 cells by suppressing intracellular 
Hsp70 expression, correlating with a downregulation of HSF-1 activity. Thus, 
resveratrol was able to significantly enhance the apoptotic effect of the anticancer drug 
17-allylamino-17-demethoxygeldanamycin that is known to augment Hsp70 levels. 
However, other studies have found that resveratrol induces Hsp70 expression in other 
cell lines. Cardile et al. (2003) reported that lower concentrations of resveratrol (50-
100µM) significantly raised Hsp70 levels in prostate cancer DU-145 cells, whilst the 
higher concentration (200µM) showed no difference in Hsp70 levels than control cells. 
Putics et al. (2008) reported that resveratrol induced the expression of Hsp70 in human 
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peripheral lymphocytes, monkey fibroblasts and human cervical cancer cell line HeLa, 
but did not demonstrate a reduction in Hsp70 levels at higher concentrations of 
resveratrol. They reported that the resveratrol-induced Hsp70 elevation synergized with 
mild-moderate heat stress to protect cells against severe heat stress. None of the studies 
investigated the cellular location of the induced Hsp70s.  
 
 
1.4.5. Combination treatments - Resveratrol and TRAIL and ethanol 
 
Resveratrol has been shown to sensitize cancer cells to cell death induced by anticancer 
agents AraC,  5-fluoro-uracil, paclitaxel and radiation therapy (Fulda and Debatin, 
2004; Sun et al., 2002; Kubota et al., 2003; Jazirehi and Bonavida, 2004; Zoberi et al., 
2002 in Delmas et al. 2004) as well as to TRAIL-induced apoptosis (Fulda and 
Debatin, 2005; Delmas et al., 2004). Relatively low concentrations of resveratrol (10-
30µM) have been shown to be effective to produce a significant sensitization effect 
(Jazirehi and Bonavida, 2004; Fulda and Debtain, 2004; Delmas et al., 2004). 
  
Several studies have linked resveratrol-induced apoptosis with modulation of death 
receptors.  Clément et al. (1998) observed that resveratrol enhanced CD95L activity in 
HL60 and T47D cells, and suggested that resveratrol-induced cell death is CD95/Fas-
signaling dependent. Delmas et al. (2004) demonstrated that resveratrol sensitised 
colon cancer cells to apoptosis induced by death receptor ligands (TNF, anti-CD95 
antibodies, TRAIL) without increasing the number of death receptors on the cell 
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membrane but by inducing the redistribution of CD95, DR4 and DR5 into lipid rafts, 
which is believed to aid DISC activation. Quercetin, another dietary polyphenol in red 
wine, has also been shown to enhance TRAIL-induced apoptosis directly by 
accumulation of death receptors into lipid rafts (Psahoulia et al., 2007). Ethanol has 
been shown to be a potent sensitizer of colon cancer cells to TRAIL-induced apoptosis 
(Vaculová et al., 2004). The effect has not been directly linked with lipid raft 
modulation, but ethanol is known to be a membrane fluidizer and causes lipid raft 
clustering at relatively low concentrations (50 mM; Nourissat et al., 2008). Thus, it is 
feasible that lipid raft aggregation is also partly responsible for the sensitization effect 
of ethanol.  
 
An important property for anticancer agents is the ability to overcome anti-apoptotic 
proteins. Whilst DNA-damaging cytotoxic drugs used to sensitise cells to death 
receptor-mediated apoptosis are unable to overcome the inhibitory effect of Bcl-2 
overexpression observed in several tumour cell types (Micheau et al., 1997; Lacour et 
al., 2003), Delmas et al. (2004) showed that resveratrol is. Delmas et al. (2004) 
suggested that the difference is caused by an ability of resveratrol to assist in stronger 
DISC formation by the modulation of lipid rafts. However, Fulda and Debatin (2005) 
showed that resveratrol was unable to overcome overexpression of Bcl-2 and FADD-
DN suggesting that these uncoupled the apoptotic effects of resveratrol (cell cycle 
arrest and surviving depletion) with the caspase cascade. This study used up to 30ng/ml 
TRAIL in Jurkat or SHEP cells whilst Delmas et al. (2004) used 100ng/ml in colon 
cancer cells, suggesting that the effect may be TRAIL dose dependent or cell type 
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specific (i.e. cells have differing sensitivities to TRAIL). Vacluova et al. (2004) 
showed that Bcl-2 or the mitochondrial pathway was not involved in the potentiation of 
TRAIL-induced apoptosis by ethanol, and proposed the involvement of other 
mechansism including modulation of anti-apoptotic signals involved in TRAIL 
resistance. Thus, it appears that although ethanol and resveratrol may have similar 
effects and both cause lipid raft aggregation, they may also differ in mechanisms to 
sensitize cells to apoptosis. It would be interesting to investigate whether a greater 
sensitization effect could be achieved by using the compounds in combination, 
particularly since ethanol is a constituent of red wine which has been proposed to be 
the most abundant source of resveratrol in the human diet.  
 
Moderate consumption of alcoholic drinks, including red wine, has been suggested to 
have heath beneficial properties (Opie and Lecour, 2007). However, the World 
Research Cancer Fund has also linked alcohol consumption with increased risk of 
cancer (Wiseman, 2008). Alcohol-free red wine may be a superior source of resveratrol 
for health. This makes sense in chemopreventive aspect. However, moderate amounts 
of ethanol has been shown to have some similar heath beneficial effects to resveratrol, 
e.g. anti-inflammatory and immune modulating properties (Szabo et al., 2007) and 
ability to sensitise cancer cells to TRAIL (Vaculová et al., 2004). Since alcoholic red 
wine is more available and more commonly consumed, it would be interesting to 
investigate the effect of the combination of ethanol and resveratrol on cancer cells, as 
well as in combination with TRAIL.  
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1.5. Bioavailability and Clinical Potential of Resveratrol 
 
There is interest in a number of different polyphenols in red wine for potential health 
benefits including protection against inflammation, atherosclerosis and cancer (Soleas 
et al., 2002). Soleas et al. (2002) used a mouse skin cancer model assessing initiation 
and promotion of cancer to compare the antitumorigenic activities of four common red 
wine polyphenols: (+)-catechin, quercetin, gallic acid, and trans-resveratrol. Whilst 
quercetin was the most effective at inhibiting tumour formation and resveratrol showed 
intermediate efficacy, the research team concluded that in terms of human consumption 
of red wine, trans-resveratrol may be the most effective anticancer polyphenol 
consumed. This is due to its relatively high concentration in red wine and much more 
efficient absorption by humans than the other polyphenols that displayed 
antitumorigenic activity, as reported by the same research team (Goldberg et al., 2003).  
 
Goldberg et al. (2003) compared how efficiently trans-resveratrol, [+]-catechin and 
quercetin were absorbed by healthy human males after oral consumption in three 
different media (white wine, grape juice and vegetable juice) and concluded that the 
absorption of resveratrol was the most efficient, and that the absorption was similar in 
aqueous and alcoholic media. However, the peak concentrations found in serum (10-
40nmol/L) were too low to be compared with in vitro findings. All polyphenols were 
predominantly present in serum as glucuronide and sulfate conjugates so that the 
research team concluded that the literature regarding the effects of the polyphenols are 
irrelevant since they are absorbed as conjugates in the human body.   
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1.6. Aims of the study 
 
Resveratrol has been shown to induce apoptosis in Jurkat cells and to a lesser extent in 
U937 cells (Park et al., 2001; Ferry-Dumanez et al, 2002; Dörrie et al., 2001; Fulda and 
Debatin, 2004). The cell lines are suitable for the study as they have been shown to be 
relatively sensitive to resveratrol. Contradictory results exist on the effect of resveratrol 
on intracellular Hsp72, whilst the effect on extracellular/surface Hsp72 has not been 
investigated. Resveratrol has been shown to sensitise Jurkat cells to TRAIL-induced 
apoptosis, but the evidence is missing for U937 cells. There are no reports on the effect 
of resveratrol and ethanol in combination despite red wine being the largest source of 
resveratrol in the Western diet (Baur and Sinclair, 2006).  
 
Suppression of intracellular Hsp72 expression is a promising mechanism to render 
cancer cells more susceptible to treatment. It is possible that resveratol causes such a 
suppression, and if not, resveratrol-induced apoptosis may be more effective at lower 
concentrations if intracellular Hsp72 are depressed. It is worth investigating the effect 
resveratrol has of surface Hsp72 expression due to the immunogenic properties of 
surface Hsp72. 
 
In view of this, the aims of the study were: 
1. to demonstrate the induction of cell death and apoptosis by resveratrol in a 
lymphoid (Jurkat) and myeloid (U937) leukaemia cell line 
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2. to demonstrate that resveratrol sensitizes the cells to TRAIL-induced apoptosis, 
and to investigate the effect of combination treatment of the cells with resveratrol, 
ethanol and TRAIL on cell death and apoptosis 
3. to investigate the effect of resveratrol on intracellular and surface Hsp72 
expression  
4. to investigate whether methods to increase or decrease intracellular Hsp72 prior to 
resveratrol treatment could modulate the sensitivity of the cells to resveratrol-




2.1. Reagents and antibodies 
 
Resveratrol was from Sigma-Aldrich (R5010). A 100mM stock solution of resveratrol 
was made up in ethanol (99.7%; VWR International, 10107). TRAIL was from 
PeproTech (310-04) of which a 50mg/ml stock solution was made up in distilled water. 
Working concentrations of resveratrol, TRAIL and ethanol were made by adding stock 
solution directly to tissue culture medium.  
 
A 100mM stock solution of Propidium Iodide (PI; Sigma, P4170) was made up in 
DPBS (Cambrex, BE17-513F) and diluted 1:20 in DPBS to provide a working 
concentration of 5mM as required. MTS was from Promega (G1112) and made up 
according to manufacturers’ instructions. Enzolyte Rh110 Caspase-3 assay kit was 
from Cambridge Bioscience (71141). Hydrogen peroxide (100 volumes solution) was 
from Fischer (H/1750/15). Trypan Blue (Sigma, T8154) was made up to a 0.4% 
solution in DPBS.  
 
FITC-conjugated Annexin-V was from BD Bioscience (556 420). FITC-conjugated 
mouse antihuman Hsp70 monoclonal antibody was from Bioquote (SPA-810-FIH). BD 
Cytofix/Cytoperm fixation and permeabilization solution was from BD Bioscience (51-
2090KZ). 
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2.2. Cell culture 
 
Jurkat E6.1 cells and U937 cells were obtained from the European Collection of Cell 
Culture (Wilshire, UK). Cell lines were maintained in RPMI culture media (Cambrex, 
BE12-702F) with 10% fetal calf serum (FCS; Cambrex, 14-801F) and 1% antibiotic 
antimycotic solution (100x; Sigma, A5955). They were kept in a humidified 
environment with 5% CO2 at 37°C and maintained at an approximate density of 5 x 105 
cells/ml by routine passage.  
 
 
2.3. Treatment of Cells with Compound or Heat Shock 
 
Prior to any treatments of cells with compound or heat shock, the appropriate cell 
density for the desired assay was determined. Total cell and viability counts were 
performed using a haemocytometer on cells diluted 1:1 with Trypan Blue. Preliminary 
experiments revealed that 2 x 105 cells/well was the optimal seeding density for cell 
viability and caspase-3 assays. A seeding density of 5 x 104 cells/well was used for 




2.3.1 Procurement of optimum parameters of heat shock and ethanol 
treatments for maximum effects on Hsp72 expression 
 
To determine the heat shock treatment that would sufficiently increase intracellular 
Hsp72 expression, sufficient volumes of Jurkat and U937 cells were divided into 6-
well plates or T25 tissue culture flasks and left in a humidified environment with 5% 
CO2 at 42°C (or 37°C for control cells) for 0.5 or 1 hr before being transferred to 37°C 
for a 0-3 hr recovery period.  
 
To determine the ethanol treatment that would sufficiently decrease intracellular Hsp72 
expression, Jurkat and U937 cells were treated with 1.25 % ethanol for various time 
periods as described in section 2.3.3. 
 
Flow cytometry was used to analyse intracellular Hsp72 after heat shock and ethanol 
treatments (section 2.5.2). 
 
2.3.2. Pre-treatment of cells with heat shock or ethanol 
 
For pre-treatment of cells with heat shock, cells were kept at 42°C for 1 hr and 
transferred to 37°C for a 3 hr recovery period before being treated with resveratrol. 
 
For ethanol pre-treatment, Jurkat and U937 cells were treated with 1.25% ethanol in 
48-well plates (as described in section 2.3.3) for 2 hours before being centrifuged at 
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500g for 5 minutes and the supernatant removed. Each cell sample was washed once by 
re-suspension in 200μL RPMI and centrifuged again at 500g for 5 minutes. Finally, the 
supernatant was removed and the cell samples were re-suspended in tissue culture 
medium containing the appropriate concentrations of resveratrol.  
 
Appropriate volumes of resveratrol to ensure that the initial cell density was 
maintained were used. Cells were treated with resveratrol for 20 hrs as described in 
section 2.3.3.  
 
2.3.3. Treatment of cells with compound  
 
Jurkat and U937 cells were added to 48-well or 96-well plates at 5 x 104 or 2 x 105 
cells/well (depending on the intended assay) and exposed in triplicate/quadruplicate 
(for cell viability and caspse-3 assays) or duplicate (for FACS analysis) to various 
concentrations of treatment compounds. Compounds (resveratrol, TRAIL and ethanol) 
were used alone or in combination, for the times indicated (e.g. 24 hrs for resveratrol, 
ethanol and TRAIL treatments alone or in combination, 2 hrs for ethanol pre-
treatments, 20 hrs for resveratrol following pre-treatment with ethanol or heat shock, 
and 0-5 hrs for ethanol alone to determine pre-treatment parameters).  
 
A vector control and dead cell control were included in experiments as appropriate. 
The vector control comprised of the concentration of ethanol included in the highest 
concentration of stock resveratrol used. The dead cell control included for cell viability 
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and caspase-3 assays was achieved by adding a 1:1 volume ratio of hydrogen peroxide 
to the assigned cell samples. For FACS analysis, heat shocked cells were included as 
dead cell controls after incubating them in a water bath at 42ºC for 2 hrs. 
 
 
2.4. Microtiter plate based assays 
 
2.4.1. Cell viability – MTS assay 
 
Treated cells were centrifuged at 500g for 5 minutes in microcentrifuge tubes and the 
supernantant discarded. The cells were resuspended in 100μL tissue culture media and 
transferred to a 96-well plate. 20μl of MTS solution was mixed into each cell 
suspension and the plate was incubated in the dark at 37ºC for 1.5 – 2 hours. 
Absorbance of the formazan product was measured at 490 nm on a bi-spectral 
fluorescent spectrophotometer (Bio-Tek). 
 
2.4.2. Cell viability – Propidium Iodide (PI) Assay 
 
Treated cells were centrifuged at 500g for 5 minutes in microcentrifuge tubes and the 
supernantant discarded. The cells were resuspended in 50μl tissue culture media and 
transferred to a 96-well plate. 20μl working concentration of PI was mixed into each 
cell suspension and the plate was incubated in the dark at room temperature for 20 
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minutes. Fluorescence was measured at Ex/Em 535/617 on a bi-spectral fluorescent 
spectrophotometer (Bio-Tek). 
 
2.4.3. Apoptosis – Caspase-3 assay 
 
Treated cells were centrifuged at 500g for 5 minutes in microcentrifuge tubes and the 
supernantant discarded. The cells were resuspended in 150μl tissue culture media and 
transferred to a 96-well plate. 50μl caspase-3 substrate solution (Cambridge 
Bioscience), made according to the manufacturers instructions, was mixed in to each 
cell suspension after which the cells were incubated in the dark at room temperature for 




2.5. Flow cytometry 
 
2.5.1. Annexin V and PI analysis 
 
Treated cells were centrifuged at 500g for 5 minutes in microcentrifuge tubes and the 
supernantant discarded. The cells were washed once by resuspending them in 150μl 
wash buffer (5% FCS in DPBS) and then transferred to a 96-well V-bottomed plate in 
which they were centrifuged at 500g for 5 minutes and the supernatant removed. 
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FITC-conjugated annexin V and PI were diluted 1:20 and 1:40, respectively, in binding 
buffer (0.1M HEPES/NaOH, 1.4M NaCl, 25 mM CaCl2). 50μl of the diluted FITC-
conjugated annexin V was added to each well and incubated in the dark at room 
temperature for 20 minutes, after which 100μl of the diluted PI was added to each well 
and the cells analysed using the BD FACS CANTO Dual Laser Flow Cytometer 
(Becton Dickinson). Control cell suspensions with no stain, only annexin V or only PI 
staining as well as heat shocked dead cell controls were included in the analysis. Equal 
volume of binding buffer was added to the wells where annexin V or PI was omitted.  
 
2.5.2. Analysis of intracellular and surface Hsp70 
 
Treated cells were centrifuged at 500g for 5 minutes in microcentrifuge tubes and the 
supernantant discarded. The cells were washed once by resuspending them in 100μl 
wash buffer (5% FCS in DPBS) and then transferred to a 96-well V-bottomed plate in 
which they were centrifuged at 500g for 5 minutes and the supernatant removed. 
 
For intracellular Hsp70 analysis, the cells were permeabilized prior to incubation with 
antibody by adding 70μl permeabilizing solution to each sample and incubating for 20 
minutes in the dark at room temperature. The cells were washed by re-suspension in 
100μl wash buffer and centrifugation at 500g for 5 minutes, after which the supernatant 
was discarded. This step was omitted for surface Hsp70 analysis where anti-Hsp70 was 
added directly after the first wash. 
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FITC-conjugated anti-Hsp70 (human) was diluted 1:2500 in wash buffer and 50μl of 
the mixture was added to each well except wells containing untreated ‘no stain’ control 
cells. The cells were incubated for 40 minutes in the dark at room temperature after 
which 100μl wash buffer was added to each well and the plate centrifuged at 500g for 
5 minutes and the supernatant discarded. All samples were resuspended in 150μl DPBS 




2.6. Statistical Analysis 
 
GraphPad Prism 5.0 was used for statistical analysis and graphical representation of 
results. Results were presented as mean ± standard error of mean (SEM). Statistical 
significance of differences in means was conducted when triplicate or quadruplicate 
results were available, and analysed using one-way ANOVA with post-hoc Dunnett or 
Bonferoni analysis or two-tailed unpaired Student’s t-test. When results were available 




3.1. Cell viability and apoptosis assays explained 
 
The PI and MTS assays are two methods to measure cell viability. Whilst PI 
fluorescence in the PI assay indicates loss of membrane integrity, formazan product 
development in the MTS assay is a measure of mitochondrial activity. PI is a 
fluorescent molecule that binds to DNA, but is unable to permeate intact cell 
membranes and can therefore be used to differentiate viable and dead cells. Loss of 
membrane integrity is a feature of necrotic and late apoptotic cells and therefore these 
cells allow PI binding, whilst viable cells do not. The MTS assay utilises the 
mechanism by which mitochondrial enzyme activity is required for the reduction of 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) and phenazine methosulfate to form a purple formazan product. The 
formazan product has an absorbance maximum at 490nm, and the level of absorbance 
is directly proportional to the mitochondrial activity of the cell sample. Loss of 
mitochondrial activity is an unspecific feature of loss of viability in different types of 
cell death e.g. apoptosis and necrosis.  
 
The EnzoLyte Rh110 Capase-3 Assay is a specific measure of apoptosis since 
activated caspase-3 is a key player in the apoptotic pathway. It measures caspase-3 
activity indirectly by measurement of the fluorescence of the Rh110 fluorophore 
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produced by the cleavage of (Z-DEVD)
2
-Rh110 by active caspase-3 (AnaSpec product 
information). 
 
Annexin V binding is also a specific measure of apoptosis, particularly early apoptosis. 
One of the first appearing features of apoptosis is the translocation of 
phosphatidylserine (PS) from the inner cell membrane to the cell surface. Annexin V 
has a high affinity for PS and thus, its binding and fluorescence of the conjugated FITC 
molecule indicates exposure of PS to the extracellular environment. 
 
3.2. Resveratrol causes cell death in a dose-dependent manner 
 
Initial experiments demonstrated that resveratrol causes cell death in a dose dependent 
manner in Jurkat and U937 cells, corresponding to caspase-3 dependent apoptosis at 
100-200µM and necrosis at higher concentrations of resveratrol (see figure 3.1).  
 
The PI assay revealed dose-dependent loss of membrane integrity reaching statistical 
significance at 50µM and above for both cell lines (p<0.05, figure 3.1A). Similarly, the 
MTS assay revealed dose-dependent loss of mitochondrial activity with statistical 
significance at 50µM and above in Jurkat cells (p<0.01) and 100µM and above in 
U937 cells (p<0.01, figure 3.1B). Loss of membrane integrity and mitochondrial 
activity independently indicate late apoptosis and necrosis. Thus, the PI and MTS 
assays demonstrated similar effects of resveratrol on cell viability. For simplicity, later 
cell viability experiments were therefore based on the PI assay alone.  
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Figure 3. 1. Dose-dependent induction of cell death via apoptosis and necrosis by resveratrol.  
 
A) PI fluorescence, B) formazan absorbance, and C) caspase-3 activity of Jurkat and U937 cells treated 
with various concentrations of resveratrol for 24 hours and analysed using the PI, MTS or caspase-3 
assay. Cell viability as measured by PI fluorescence was significantly reduced by 50–400μM resveratrol 
in both cell lines (A; p<0.05 or p<0.01). Cell viability as measured by formazan absorbance was 
significantly reduced by 50–400μM resveratrol in U937 cells (B; p<0.05 or p<0.01) and 100–400μM in 
Jurkat cells (B; p<0.01). Caspase-3 activity was significantly increased by 100–200μM resveratrol (C; 
p<0.01) and decreased at 400μM compared with 200μM in both cell lines (C; p<0.001). Values are 
shown as mean ± standard error (SEM) of samples in quadruplicate. Statistical significance was analysed 
using one-way ANOVA with post-hoc Dunnett test and two-tailed unpaired Student’s t-tests. Treated 
versus untreated cells: * p<0.05, ** p<0.01. Cells treated with 200μM versus 400μM resveratrol: # 
p<0.001. 
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The caspase-3 assay showed that 100-200µM resveratrol caused increased caspase-3 
activity (p<0.01), and caspase-3 activity was significantly reduced at the higher 
concentration of 400µM (p<0.01 in Jurkat cells and p<0.05 in U937 cells; see figure 
3.1C), indicating a shift from apoptosis to necrosis as the main form of cell death above 
200µM resveratrol. A raise in caspase-3 activity was not seen at concentrations of 
resveratrol <100µM despite such concentrations causing significant reduction in cell 
viability.  
 
The above findings were confirmed by measuring annexin V binding and PI 
fluorescence of resveratrol-treated cells using flow cytometry. Dose-dependent loss of 
cell viability as measured by PI fluorescence corresponded to an increase in annexin V 
presentation at 25, 50 and 100µM resveratrol (see figure 3.2). Flow cytometry dot plots 
revealed that the majority of dying cells at all concentrations caused both annexin V 
binding and PI fluorescence, suggesting late apoptosis/necrosis (see figure 3.3). 
Resveratrol caused a reduction in cell viability from 91% viable cells in the untreated 
sample to 63% viable cells in the sample treated with 100µM resveratrol (see figure 
3.4). 
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Figure 3. 2. Dose-dependent induction of cell death by resveratrol in U937 cells, as analysed with flow 
cytometry.  
 
U937 cells treated with increasing concentrations of resveratrol for 24 hours caused a dose-dependent 
increase in Annexin V presentation as measured by fluorescence of FITC-conjugated Annexin V, and a 
dose-dependent loss of cell viability as measured by PI fluorescence. Statistical analysis was limited due 
to there being only two replicates per sample. Non-linear regression was performed, and R2 >0.99 
against a quadratic curve fit for both data sets. This suggests that both curves are quadratic in nature and 
that there are statistically significant increases in FITC-Annexin V and PI fluorescence. Values are 











Figure 3. 3. Dot plots from flow cytometry analysis of resveratrol (RSV)-treated cells showing 
distribution of the cell population based on state of viability.  
 
U937 cells were treated with 0μM (a), 25μM (b), 50μM (c) and 100μM (d) resveratrol for 24 hours and 
apoptosis and cell viability determined using the Annexin V and PI assays using flow cytometry. PE-A 
indicates PI fluorescence (mean fluorescence intensity; MFI) and FITC-A indicates fluorescence of 
FITC-conjugated Annexin V (MFI). The bottom left quadrant of the plots shows the viable cell 
population that did not cause either PI or FITC-Annexin V fluorescence; the top left quadrant shows the 
cell population that displayed necrosis by impaired membrane integrity and PI fluorescence only; the 
bottom right quadrant shows the cell population displaying apoptosis by Annexin V binding and FITC 
fluorescence only; and the top right quadrant shows the cell population displaying late apoptosis/necrosis  
by causing both PI and FITC fluorescence, thus indicating apoptosis by allowing Annexin V binding and 
necrosis by the impaired membrane integrity. The dot plots reveal that the unviable cell populations 
were mostly in late apoptotic/necrotic state and the unviable population size increased with increasing 
concentrations of resveratrol. 
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Figure 3. 4. Resveratrol causes a dose-dependent reduction in cell viability as measured by flow 
cytometry.  
 
Flow cytometry analysis of U937 cells treated with 0-100μM resveratrol indicated progressive loss of 
cell viability measured by the fluorescence of either FITC-conjugated Annexin V or PI. Values are 
shown as mean ± SEM of samples performed in duplicate. 
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3.3. Low concentrations of resveratrol cause raised intracellular and 
surface levels of Hsp72; higher concentrations of resveratrol cause 
further increase in surface levels of Hsp72 but no change or decrease in 
intracellular levels of Hsp72  
 
Intracellular and surface levels of Hsp72 of Jurkat cells treated with resveratrol for 24 
hours were analysed using flow cytometry. Cells treated with 12.5, 25 and 50µM 
resveratrol had significantly higher levels of intracellular Hsp72 than untreated cells 
(p<0.05; see figure 3.5). In cells treated with 100µM, the levels were unchanged from 
those of untreated cells, and above 100µM the levels were significantly reduced, 
presumably due to the higher degree of necrosis occurring at these higher 
concentrations. Surface levels of Hsp72 increased with increasing concentrations of 
resveratrol, statistically significant at 25µM and above (p<0.01; see figure 3.5). The 
results indicate that lower concentrations of resveratrol (12.5-50µM) induces increased 
Hsp72 expression at a sufficient level to allow increased intracellular levels as well as 
export for elevated surface expression. It is assumed that the increased degree of 
necrosis occurring at higher concentrations of resveratrol is responsible for the 
appearance of increased surface expression of Hsp72, and that this is not a true 




























































Figure 3. 5. Intracellular and surface Hsp72 of Jurkat cells treated with resveratrol.  
 
Jurkat cells treated with various concentrations of resveratrol for 24 hours were analysed for levels of 
intracellular and surface Hsp72 by anti-Hsp72 binding using flow cytometry. Levels of intracellular 
Hsp72 were significantly increased by 12.5, 25 and 50μM resveratrol (p<0.05 or p<0.01), unchanged by 
100 μM, and decreased from control by 200μM resveratrol (p<0.05). Levels of surface Hsp72 were 
significantly increased by treatment with 25, 50, 100 and 200μM resveratrol (p<0.01). Values are shown 
as mean ± SEM of samples done in triplicate. Statistical significance was analysed using one-way 
ANOVA and post-hoc Dunnett test. Treated versus untreated cells: * p <0.05, ** p<0.01. 
 
3.4. Resveratrol sensitizes leukaemia cells to TRAIL-induced apoptosis 
and displays a synergistic effect with ethanol on cell death and TRAIL-
induced apoptosis 
 
Dose response experiments with TRAIL and ethanol were performed on Jurkat and 
U937 cells using the PI assay to determine sub-lethal concentrations of a 24 hr 
treatment. No concentration of TRAIL (0-100ng/ml) had any effect on cell viability 
(figure 3.6), indicating that higher concentrations are required to cause cell death in the 
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cell lines used. Concentrations of ethanol above 1.25% significantly reduced cell 
viability in both cell lines (p<0.01; figure 3.7), whilst 1.25% and lower concentrations 
remained sub-lethal. 25ng/ml TRAIL and 1.25% ethanol have been successfully used 
as sub-lethal concentrations on Jurkat cells in the laboratory previously. Therefore, 
these concentrations were initially selected for use in combination treatment 
experiments. 
 























Figure 3. 6. Effect on cell viability of various concentrations of TRAIL.  
 
Jurkat (striped fill) and U937 (crossed fill) cells were treated with various concentrations of TRAIL for 
24 hours and cell viability analysed with the PI assay. Cells treated with hydrogen peroxide acted as 
necrosis controls. Only the necrosis controls showed a statistically significant reduction in cell viability 
compared with untreated cells. Values are shown as mean ± SEM of samples performed in 
quadruplicate. Statistical significance was analysed using one-way ANOVA and post-hoc Dunnett test. 
Treated versus untreated cells: ** p <0.01. 
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Figure 3. 7. Effect of ethanol treatment on cell viability. 
 
Jurkat (solid line) and U937 (dashed line) cells were treated with various concentrations of ethanol for 
24 hours and cell viability analysed with the PI assay. Statistically significant reduction in cell viability 
compared with untreated cells was seen at 2.5% and 5% ethanol (p<0.01). Values are shown as mean ± 
SEM of samples performed in quadruplicate. Statistical significance was analysed using one-way 
ANOVA and post-hoc Dunnett test. Treated versus untreated cells: ** p <0.01. 
 
Dose response experiments with resveratrol were performed on Jurkat and U937 cells 
treated alone or alongside 25ng/ml TRAIL, 1.25% ethanol or both. Cell viability was 
analysed using the PI assay. TRAIL and ethanol both had independently additive 
effects to resveratrol on loss of cell viability (p<0.05; figure 3.8). However, the 
combination of all three compounds produced no greater effect than the combination of 
resveratrol and 1.25% ethanol. It was thought that the large effect on cell viability 
caused by resveratrol in combination with 1.25% ethanol masked a possible extra 
additive effect of TRAIL. Therefore, the ethanol concentration was reduced to 0.5% 
and the experiment repeated.  
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Figure 3. 8. Effect on cell viability of combination treatments with resverarol (RSV) and 25ng/ml 
TRAIL, or 1.25% ethanol, or both.  
Jurkat (A) and U937 (B) cells were treated with various concentrations of resveratrol alone or together 
with 25ng/ml TRAIL or 1.25% ethanol or both for 24 hours and cell viability analysed with the PI assay. 
TRAIL and ethanol appeared to both have independently additive effects on the dose-dependent loss of 
cell viability induced by resveratrol, but no additive effect to resveratrol of TRAIL and ethanol in 
combination with each other was seen. Values are shown as mean ± SEM of samples performed in 
quadruplicate. Statistical significance was analysed using one-way ANOVA and post-hoc Bonferoni test. 
Statistical significance: a) p<0.05 between ‘RSV only’ and ‘RSV + TRAIL’; b) p<0.01 between ‘RSV 
only’ and ‘RSV + TRAIL’; c) p<0.05 between ‘RSV only’ and ‘RSV + ethanol’; d) p<0.001 between 
‘RSV only’ and ‘RSV + ethanol’; e) p<0.05 between ‘RSV only’ and ‘RSV + TRAIL + ethanol’; f) 
p<0.001 between ‘RSV only’ and ‘RSV + TRAIL + ethanol’; g) p<0.001 between ‘RSV + TRAIL’ and 
‘RSV + ethanol’; h) p<0.05 between ‘RSV + TRAIL’ and ‘RSV + TRAIL + ethanol’; i) p<0.001 
between ‘RSV + TRAIL’ and ‘RSV + TRAIL + ethanol’; j) p<0.01 between ‘RSV + TRAIL’ and ‘RSV 
+ TRAIL + ethanol’. 
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Figure 3. 9. Effect on cell viability of combination treatments with resveratrol (RSV) and 25ng/ml 
TRAIL, or 0.5% ethanol, or both. 
Jurkat (A) and U937 (B) cells were treated with various concentrations of resveratrol alone or together 
with 25ng/ml TRAIL or 0.5% ethanol or both for 24 hours and cell viability analysed with the PI assay. 
TRAIL and ethanol appeared to both have independently additive effects as well as a combined additive 
effect on the dose-dependent loss of cell viability induced by resveratrol. Values are shown as mean ± 
SEM of samples done in quadruplicate. Statistical significance was analysed using one-way ANOVA 
and post-hoc Bonferoni test. Statistical significance: a) p<0.001 between ‘RSV only’ and ‘RSV + 
TRAIL’; b) p<0.01 between  ‘RSV only’ and ‘RSV + TRAIL’; c) p<0.05 between  ‘RSV only’ and 
‘RSV + TRAIL’; d) p<0.001 between  ‘RSV only’ and ‘RSV + ethanol’; e) p<0.01 between  ‘RSV only’ 
and ‘RSV + ethanol’; f) p<0.001 between  ‘RSV only’ and ‘RSV + TRAIL + ethanol’; g) p<0.01 
between ‘RSV only’ and ‘RSV + TRAIL + ethanol’; h) p<0.001 between ‘RSV + TRAIL’ and ‘RSV + 
ethanol’; i) p<0.05 between ‘RSV + TRAIL’ and ‘RSV + ethanol’; j) p<0.01 between ‘RSV + TRAIL’ 
and ‘RSV + TRAIL + ethanol’; k) p<0.001 between ‘RSV + TRAIL’ and ‘RSV + TRAIL + ethanol’; l) 
p<0.05 between ‘RSV + TRAIL’ and ‘RSV + TRAIL + ethanol’; m) p<0.05 between ‘RSV + ethanol’ 
and ‘RSV + TRAIL + ethanol’. 
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Cell viability was again analysed using the PI assay and apoptosis using the caspase-3 
assay. With 0.5% ethanol, additive effects on cell viability and apoptosis/necrosis were 
seen with all combination treatments and the largest effect seen with the triple 
combination of resveratrol, 0.5% ethanol and 25ng/ml TRAIL (p<0.05; figures 3.9 and 
3.10). Double treatments with resveratrol and 0.5% ethanol or resveratrol and 25ng/ml 
TRAIL had similar effects on cell death and apoptosis, although resveratrol and 0.5% 
ethanol was somewhat more apoptotic/cytotoxic causing significantly greater cell death 
at 50µM resveratrol and significantly greater caspase-3 activity at 25 and 50µM 
resveratrol (p<0.05). The additive effect of triple treatment was particularly prominent 
with 50µM resveratrol in the PI assay (p<0.05), and 25µM resveratrol in the caspase-3 
assay (p<0.01). Whereas no decrease of caspase-3 activity was seen with single 
treatment with resveratrol, caspase-3 activity decreased at concentrations above 100µM 
in the double treatments, and above 50µM in the triple combination treatments. This 
indicates a shift from apoptosis to necrosis occurring at lower concentrations of 
resveratrol, and thus greater levels of toxicity occurring with combination treatments.  
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Figure 3. 10.  Effect of combination treatments with resveratrol (RSV) and 25ng/ml TRAIL, or 0.5% 
ethanol, or both, on caspase-3 dependent apoptosis. 
 
U937 cells were treated with various concentrations of resveratrol alone or together with 25ng/ml 
TRAIL or 0.5% ethanol or both for 24 hours and apoptosis measured with the caspase-3 assay. TRAIL 
and ethanol appeared to both have independently additive effects as well as a combined additive effect 
on the dose-dependent apoptotic-to-necrotic effect of resveratrol. A significant increase in caspase-3 
activity was measured with each treatment added to resveratrol at 25μM (p<0.001). The highest caspase-
3 activity achieved after single treatment was with 200μM resveratrol, whereas cells treated with 200μM 
+ TRAIL, ethanol or both displayed decreased apoptosis from a peak at 100μM resveratrol, suggesting a 
shift to necrosis. Values are shown as mean ± SEM of samples done in quadruplicate. Statistical 
significance was analysed using one-way ANOVA and post-hoc Bonferoni test. Statistical significance:  
a) p<0.001 between ‘RSV only’ and ‘RSV + TRAIL’ 
b) p<0.001 between ‘RSV only’ and ‘RSV + ethanol’ 
c) p<0.001 between ‘RSV only’ and ‘RSV + TRAIL + ethanol’ 
d) p<0.01 between ‘RSV + TRAIL’ and ‘RSV + ethanol’ 
e) p<0.05 between ‘RSV + TRAIL’ and ‘RSV + ethanol’ 
f) p<0.01 between ‘RSV + TRAIL’ and ‘RSV + TRAIL + ethanol’ 
g) p<0.001 between ‘RSV + TRAIL’ and ‘RSV + TRAIL + ethanol’ 
h) p<0.01 between ‘RSV + ethanol’ and ‘RSV + TRAIL + ethanol’ 




The results were confirmed by microscope views of treated cells showing greater 
degrees of apoptosis and necrosis at higher concentrations of compounds used. The 
additive effect of TRAIL on the effect of resveratrol on cell death was also confirmed 
by cell counts of samples treated using the trypan blue exclusion test (data not shown).  
 
3.5. Manipulation of Hsp72 expression prior to resveratrol treatment 
 
To determine whether modification of intracellular Hsp72 levels can alter sensitivity of 
cells to resveratrol-induced cell death, Jurkat and U937 cells were exposed to mild, 
non-lethal heat shock or 1.25% ethanol prior to treatment with resveratrol for 20 hrs.  
3.5.1. Stimulating Hsp72 expression by pre-treating cells to heat shock prior 
to resveratrol treatment increases resistance of cells to resveratrol-induced 
cell death 
 
Jurkat and U937 cells were subjected to various time periods of heat shock and 
recovery in order to determine parameters to induce Hsp72 expression without causing 
cell death. Initial experiments revealed that a 2 hr heat shock at 42°C caused significant 
cell death (data not shown), whereas 1 hr was known not to cause cell death (by 
communication with Nina Dempsey). Therefore 0.5 and 1 hr heat shock incubations 
were used. The greatest level of intracellular Hsp72 was obtained after an 1 hr 
incubation at 42°C followed by a 3 hr recovery period at 37°C (p<0.01; figure 3.11).  
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Figure 3. 11. The effect of mild heat shock on levels of intracellular Hsp72 (iHsp72). 
 
Jurkat and U937 cells were subjected to heat shock for 0.5 hour (A) or 1 hour (B) by incubation at 42°C, 
then allowed to recover at 37°C for 0–3 hours before iHsp72 levels by anti-Hsp72 binding was analysed 
using flow cytometry. Levels of iHsp72 were significantly decreased at 0-2 hours recovery following 0.5 
hour heat shock (p<0.01), and not significantly increased from untreated cells after 3 hours recovery. 
Levels of iHsp72 were significantly decreased at 0-1 hour recovery in Jurkat cells (p<0.05), and 0 and 2 
hours recovery in U937 cells (p<0.05 and p<0.01), but significantly increased after 3 hours recovery in 
both cell lines (p<0.01). Values are shown as mean ± SEM of samples conducted in triplicate for U937 
cells and quadruplicate for Jurkat cells. Statistical significance was analysed using one-way ANOVA 
and post-hoc Dunnett test. Treated cells versus untreated cells: * p<0.05, ** p<0.01. 
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Figure 3. 12. Pre-treatment of cells with heat shock results in increased resistance to resveratrol-
induced cell death.  
 
Jurkat (A, B) and U937 (C, D) cells were incubated with various concentrations of resveratrol for 20 
hours following an initial expose to heat shock (1 hour incubation at 42ºC followed by a 3 hours 
recovery period at 37ºC) or no heat shock (control cells were kept at 37ºC for the initial 4 hours). After 
treatment, a PI assay (A, C) and caspase-3 assay (B, D) were conducted. Following exposure to initial 
heat shock, Jurkat cells treated with 50 and 100μM resveratrol showed a statistically significant 
reduction (p<0.05) in caspase-3 activity (B), and U937 cells treated with 25μM (p<0.05) and 100μM 
(p<0.01) resveratrol a statistically significant increase in cell viability (C) compared with control cells. 
No statistically significant difference in cell viability in Jurkat cells (A) or caspase-3 activity in U937 
cells (D) was seen. Values are shown as mean ± SEM of samples performed in triplicate or 
quadruplicate. Statistical analysis was conducted using two-tailed unpaired Student’s t-tests. Heat shock 
treated cells versus control cells: * p<0.05, ** p<0.01. 
 
Jurkat and U937 cells were pre-treated with heat shock for 1 hr at 42°C followed by a 3 
hr recovery before incubation with various concentrations of resveratrol for 20 hrs. Pre-
treatment of Jurkat cells to heat shock caused a small but significant reduction in 
sensitivity to resveratrol-induced cell death (p<0.05 at 50 and 100µM resveratrol; 
figure 3.12A). A small but significant reduction in sensitivity to resveratrol-induced 
apoptosis was detected in Jurkat cells with the caspase-3 assay (p<0.05; figure 3.12B), 
and to resveratrol-induced cell death in U937 as measured with the PI assay (p<0.05; 
figure 3.12C). This effect was not statistically significant for the PI assay in Jurkat cells 
or for the caspase-3 assay in U937 cells (figure 3.12A and D).  
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3.5.2. Suppressing Hsp72 expression by pre-treating cells to ethanol prior to 
resveratrol treatment is insufficient to sensitise cells to resveratrol-induced 
cell death.  
 
A time course of treatment of Jurkat and U937 cells with 1.25% ethanol was conducted 
in order to determine parameters to inhibit HSP expression without causing cell death. 
A concentration of 1.25% ethanol was used based on previously successful results with 
this concentration (communication with Nina Dempsey) and it was previously 
ascertained that a 24 hr treatment of cells with this concentration did not cause 
significant cell death (figure 3.7). A 2 hr treatment of Jurkat cells with 1.25% ethanol 
was found to cause the largest decrease in intracellular Hsp72 (p<0.05; figure 3.13). 
This data was obtained in collaboration with Nina Dempsey.  
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Figure 3. 13. The effect of ethanol on levels of intracellular Hsp72 (iHsp72) in Jurkat cells.  
 
Jurkat cells were treated with 1.25% ethanol for various durations and levels of iHsp72 analysed by anti-
Hsp72 binding with flow cytometry. A significant decrease in iHsp72 levels from untreated cells was 
seen after 2 and 4 hours incubation with ethanol (p<0.05), the greatest reduction being after 2 hours. 
After 4 hours incubation, the levels of iHsp72 increased to similar levels as untreated cells at 5 hours 
incubation. Values are shown as mean ± SEM of samples performed in triplicate. Statistical significance 
was analysed using one-way ANOVA and post-hoc Dunnett test. Treated cells versus untreated cells: * 
p<0.05. These data were collected in collaboration with Nina Dempsey.  
 
Jurkat and U937 cells were pre-treated with 1.25% ethanol for 2 hrs before incubation 
with various concentrations of resveratrol for 20 hrs. Pre-treatment with ethanol had no 
effect on the sensitivity of cells to resveratrol-induced cell death in either cell line 
(figure 3.14A-D).  
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Figure 3. 14. Pre-treatment of cells with ethanol had no effect on sensitivity of cells to resveratrol-
induced cell death.  
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Jurkat (A, B) and U937 (C, D) cells were incubated with various concentrations of resveratrol for 20 
hours following an initial expose to ethanol (2 hour incubation with 1.25% ethanol) or no exposure to 
ethanol. After treatment, a PI assay (A, D) and caspase-3 assay (B, C) were conducted. No significant 
differences in cell viability or caspase-3 activity were seen in Jurkat or U937 cells between cells exposed 
to ethanol and not (A-D). Values are shown as mean ± SEM of samples done in triplicate or 




Resistance of cancer cells to apoptosis remains a major obstacle to the efficacy of 
anticancer treatments, and the identification of methods to decrease or counteract this 
resistance is paramount to the progression of cancer management. 
 
Resveratrol has gained much attention for its anti-cancer properties. Research has 
demonstrated its chemopreventive activity and investigating its potential as a 
chemotherapeutic agent (Signorelli and Ghidoni, 2005). Resveratrol has been found to 
cause cell cycle arrest and induce apoptosis of a variety of different cancer cell lines in 
vitro and reduce tumour mass in animal models in vivo (Jang et al., 1997; Garvin et al., 
2006; Kalra et al., 2008; Clément et al., 1998; Bernhard et al., 2000; Dörrie et al., 
2001; Delmas et al., 2003). However, the true clinical potential of resveratrol is 
unknown. It will depend on the concentration needed for therapeutic efficacy, its 
bioavailability, and its level of toxicity. Relatively high concentrations of resveratrol 
may be needed for effective apoptosis of certain cancer cell lines (Wang et al., 2005), 
which may increase the risk of toxicity and be difficult to achieve in situ. Thus, it is 
useful to consider the use of resveratrol in combination with other anticancer 
agents/therapies that allow lower concentrations to be needed for efficacy.   
 
TRAIL is a promising anti-cancer agent that induces apoptosis specifically in cancer 
cells, although resistance is also common (Clemons and Anderson, 2006). Ethanol has 
also been shown to induce apoptosis and sensitise cancer cells to TRAIL-induced 
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apoptosis (Vacluova et al., 2004). Both TRAIL and ethanol are relevant for use in 
combination therapy with resveratrol. Resveratrol has been observed to sensitise cells 
to TRAIL-induced apoptosis previously, and ethanol is a constituent of red wine and 
often used as a vector or solvent for other drugs. Both ethanol and resveratrol have 
been shown to cause lipid raft aggregation, but may differ in their effect on 
downstream signalling events (Delmas et al., 2004; Vaculová et al., 2004; Fulda and 
Debatin, 2005). No previous studies have investigated the effect of alcohol and 
resveratrol in combination with the aim to induce apoptosis, or the combination effect 
on TRAIL-induced apoptosis despite that the major source of resveratrol in the 
Western diet is from alcoholic red wine (Baur and Sinclair, 2006).  
 
Aggregation of lipid rafts is closely linked with the heat shock response, as changes in 
the lipid domain may signal a stress response and induce the expression of Hsps. Hsps 
are often elevated in cancer cells, including leukaemia cells (Schmitt et al., 2007; 
Lanneau et al., 2008). Intracellular Hsp72 has been shown to be a strongly anti-
apoptotic and confer cancer cells with resistance to apoptosis (Clemons and Anderson, 
2006). On the other hand, surface Hsp70 displays immunological properties and may 
induce elimination of cancer cells. Thus, therapies to reduce intracellular Hsp70 levels 
and increase surface/extracellular Hsp70 have shown promise in sensitising cancer 
cells to apoptosis (Lanneau et al., 2008; Rashmi et al., 2004).  
 
Bearing the above in mind, studies were designed to: 1) investigate the effect of 
resveratrol on two types of leukaemia cells in vitro alone or in combination with 
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ethanol, TRAIL or both, and 2) investigate the effect of resveratrol on both intracellular 
and surface Hsp72 expression and whether up- or downregulating Hsp72 expression 
can alter the cytotoxic effect of resveratrol.   
 
4.1. Induction of cell death by resveratrol occurs by apoptosis or necrosis 
depending on concentration 
 
In this study, a 24 hour incubation with resveratrol caused dose-dependent cell death in 
leukaemia cell lines Jurkat and U937 in the concentration range of 50µM and above. 
Cell death was indicated as late apoptosis or necrosis by disruption of membrane 
integrity measured with the PI assay and reduction in mitochondrial activity measure 
by the MTS assay. Apoptosis was indicated by a rise in caspase-3 activity and was 
significantly induced at 100-200µM resveratrol, but sharply declined above 200µM, 
suggesting a transition from apoptosis to necrosis occurred at the higher 
concentrations. The results were confirmed by FACS analysis using annexin-V 
presentation and PI staining.  
 
These and similar assays have been used in previous studies investigating the effect of 
resveratrol on cell viability and apoptosis of various cell types. Limitations of the 
assays include the ability of the PI and MTS assays only to detect features of cell death 
and caspase-3 assay only to detect levels of a specific caspase generally involved in 
apoptosis. However, they are considered to be valid and reliable assays. The results 
gain validity by confirmation with FACS analysis which is able to better characterise 
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the cell population by measuring parameters involved in early and late apoptosis and 
necrosis. Resveratrol has been shown to induce apoptosis via caspase-3 activation in 
U937 cells previously (Park et al., 2001). However, research by Bernhard et al. (2000) 
suggested that caspase-6 was the essential caspase while caspase-3 was activated to a 
much lesser extent in CEM-C7H2 and Jurkat cells. 
 
It is worth noting that the lowest concentration (50µM) of resveratrol that induced 
significant cell death as detected in the PI and MTS assays did not correlate with an 
increase in caspase-3 activity. Thus, what form of cell death was induced by 50µM 
resveratrol? It was assumed to be apoptosis due to existing literature indicating that 
apoptosis is likely to occur at the concentration, and because apoptosis was shown to 
occur at higher concentrations followed by a shift to necrosis only at the highest 
concentrations of resveratrol used. The lack of significant caspase-3 activity at 50µM 
resveratrol could be due to increased caspase-3 activity not remaining elevated for 
detection after 24 hours treatment, or other flaws with the experiment. It is also 
possible that apoptosis was independent of caspase-3 at the lower concentrations of 
resveratrol. It is certain that the results would have benefitted from an increased 
number of repeats and review of the methodology to validate the result.  
 
Efficacious concentrations of resveratrol to induce apoptosis have previously been 
found to be ~20–100µM after 8 – 72 hours incubation (Surh et al., 1999; Clément et 
al., 1998; Gescher & Steward, 2003; Dörrie et al., 2001; Ferry-Dumanez et al., 2002; 
Cecchinato et al., 2007; Bernhard et al., 2000; Park et al., 2001). It is difficult to 
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determine the lowest effective dose due to differing or lacking statistical methods used 
to determine significance. 
 
In contrast to apoptosis induction, Ferry-Dumanez et al. (2002) reported that 50% 
growth inhibition during 3 days incubation was achieved with 13.42µM and 16.09µM 
resveratrol in Jurkat and U937 cells, respectively. Hence, the cell lines were shown to 
be similar in sensitivity to resveratrol and display greater sensitivity than several other 
leukaemia cell lines (Ferry-Dumanez et al., 2002; Dörrie et al., 2001).  
 
Thus, the findings of this study generally comply with the results of previous studies in 
demonstrating that Jurkat and U937 cells are of similar sensitivity to resveratrol-
induced apoptosis and that this occurs at 50-200µM resveratrol after 24 hours 
incubation, notably a slightly higher concentration range than previously reported, and 
other studies have noted necrosis as the main form of cell death at 200µM (Cardile et 
al., 2003). The FACS analysis in this study only included up to 100µM resveratrol; it 
would have been interesting to use higher concentrations to further investigate the 
transition from apoptosis to necrosis.  
 
It is worth noting that research exists that indicates that Jurkat cells are relatively 
resistant to resveratrol-induced apoptosis (Wang et al., 2005), contrary to the presented 
results. It is difficult to explain this discrepancy since the presented study and others 
previously have demonstrated the efficacy of resveratrol-induced cell death in Jurkat 
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cells. It is proposed that a different type of Jurakt cells may have been used that lacked 
a vital mechanism for resveratrol-induced cell death. 
 
Whereas only dose-dependent activity was demonstrated here, other studies have 
demonstrated time-dependent activity also, showing an increase in resveratrol-induced 
growth arrest and apoptosis after 24, 48, 72 and 96 hours incubation (Clément et al., 
1998; Dörrie et al., 2001; Fulda and Debatin, 2004). Other time points than 24 hours 
were not included in this study since significant apoptosis was shown to occur, shorter 
incubation times proved less efficacious (data not shown), and longer incubation times 
were not considered beneficial to the findings.  
 
4.2. Resveratrol sensitizes leukaemia cells to TRAIL-induced apoptosis 
and displays a synergistic effect with ethanol on cell death and TRAIL-
induced apoptosis 
 
Combination treatments with resveratrol and sub-lethal concentrations of ethanol or 
TRAIL showed synergistic effects on dose-dependent cell death. The inclusion of the 
highest non-lethal concentration of ethanol (1.25%) abolished any additional apoptotic 
effect of TRAIL, suggesting that the concentration was relatively toxic. A lower, less 
toxic concentration of ethanol was therefore selected for further investigations (0.5%) 
and unmasked an additive effect on cell death with each of the three compounds 
included in the treatment. Thus, treatment with all compounds together (resveratrol, 
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ethanol and TRAIL) showed the greatest efficacy with significantly greater apoptotic 
cell death occurring at 12.5 and 25µM resveratrol than the other treatments. However, 
this triple treatment also showed the greatest toxicity with a progression from apoptosis 
to necrosis occurring at a lower concentration of resveratrol (25-50µM) than the other 
combination treatments (100-200µM). This toxicity may be cause for concern. 
However, it is promising that despite displaying much lower toxicity the double 
combination treatments with ethanol or TRAIL caused significantly higher apoptosis 
than resveratrol alone at low concentrations (25–100µM) resveratrol. This shows 
promise for the use of resveratrol as a sensitising agent for TRAIL-induced apoptosis 
and highlights that apoptosis may be enhanced by resveratrol and ethanol in 
combination. It may be feasible to overcome some toxicity of the triple treatment by 
using pre-treatments of some of the compounds in stead of combination treatments, e.g. 
Delmas et al. (2004) and Fulda and Debatin (2004) used 24 hour pre-treatments with 
resveratrol in colon cancer cells or Jurkat cells before adding a further anticancer agent 
(TRAIL and AraC, respectively) and showed that resveratrol significantly sensitised 
the cells to apoptosis. 
 
In summary, the results presented in this section confirm previous reports that 
resveratrol sensitises Jurkat cells to TRAIL-induced apoptosis (Fulda and Debatin, 
2005), and reports for the first time that this is also the case in U937 cells. Whilst Fulda 
and Debatin (2005) required 10-30ng/mL TRAIL and 100µM resveratrol to see a 
significant increase in apoptosis, this study shows that with 25ng/mL TRAIL only 
25µM resveratrol was required for a significantly raised apoptotic effect. Delmas et al. 
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(2004) observed a sensitising effect with 10-30µM resveratrol, but this was after a 48 
hr incubation and with 100ng/mL TRAIL which was believed to by cytotoxic on its 
own in the cells used. Thus, the results presented appear of equivalent or better efficacy 
than previously reported.  
 
This study highlights for the first time that the combined use of resveratrol and ethanol 
displays an enhanced apoptotic effect without excessive toxicity compared with 
TRAIL combination therapy. Significantly enhanced apoptosis was achieved with 
0.5% ethanol at as low as 25µM resveratrol compared with resveratrol alone. These 
concentrations are significantly lower than those used by Vaculová et al. (2004) who 
used 4% ethanol and 100ng/ml TRAIL to show a significant sensitising effect of 
ethanol on TRAIL-induced apoptosis in colon cancer cells. However, colon cancer 
cells are known to be relatively resistant to ethanol and leukaemia cells based on the 
data presented appear to be more sensitive. Nourissat et al. (2008) observed lipid raft 
clustering with 50mM (~0.29%) ethanol. Thus, it is reasonable to assume that lipid raft 
clustering may occur at 0.5% ethanol unless there are vast differences in the effects 
produced in the different cell types.  
 
The mechanism behind the synergistic effect of ethanol and resveratrol was not 
investigated. However, ethanol was shown in later results to depress Hsp72 levels 
which may in part have enhanced the apoptotic effect of resveratrol. However, there 
are likely to be other mechanisms involved considering that ethanol and resveratrol 
both modify lipid raft aggregation, but display differing effects on downstream 
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signalling (i.e. resveratrol may depend on mitochondria for apoptosis induction and 
ethanol not), and are both able to sensitise cells to TRAIL-induced apoptosis. Thus, the 
mechanisms behind the synergy warrant further investigation.  
 
It is important to note that resveratrol has previously been investigated as a compound 
with promise to reduce ethanol toxicity, the opposite aim of the current study. Chan 
and Chang (2006) presented such a study using K562 leukaemia cells. Using 
incubations of 200-300mM (11.5-17.25%) ethanol they observed that low 
concentations of resveratrol (10-25µM) reduced apoptosis and may be protective 
against ethanol-induced toxicity, but higher (100-200µM) concentrations of resveratrol 
enhanced apoptosis and produced a combined increased cytotoxic effect. This study 
highlights differing effects occurring from different concentrations used. Chan and 
Chang (2006) used 20-35-fold higher concentrations of ethanol than the current study 
but required 100µM resveratrol to induce augmented apoptosis and therefore does not 
agree with the presented findings in which enhanced apoptosis was achieved with 0.5% 
ethanol and 25µM resveratrol. This may be due to the vastly different concentrations of 
ethanol and the different cell line used, as K562 cells have been shown to be more 
resistant to resveratrol than Jurkat and U937 cells (Ferry-Dumazet et al., 2002). 
 
It would have been interesting to have investigated the level of apoptosis induced by 
ethanol and TRAIL alone to compare the sensitizing effects of reveratrol and ethanol 
on TRAIL-induced apoptosis. Resveratrol is considered to be less toxic than ethanol, 
although efficacious concentrations may be harder to achieve in vitro. 
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It is important to note that although 0.5% ethanol (equivalent to 0.4g/dl) is not toxic to 
leukaemia cells in vitro, equivalent concentrations in human blood have been linked 
with acute alcohol poisoning (Jones and Holmgren, 2003). Vonghia et al. (2008) report 
that blood alcohol concentrations as low as 0.05g/dl can cause change in behaviour. 
This highlights the unsuitability of the concentrations of ethanol used here to in vivo or 
clinical use, but is valuable by showing the potential of ethanol or a similar-acting 




4.3. Effect of resveratrol on Hsp72 expression 
 
In this study, 12.5-50µM resveratrol caused raised levels of intracellular Hsp72 
compared with untreated control. The elevation peaked at 25µM and declined at 50µM. 
In previous results, these low concentrations failed to demonstrate caspase-3 dependent 
apoptosis although 50µM caused significant cell death as indicated by the PI and MTS 
assays. Elevation of intracellular Hsp72 may have protected the cells from apoptosis at 
low concentrations of resveratrol, whereas higher concentrations caused no change to 
or decreased Hsp72 levels at the top concentration of 200µM and thus allowed 
apoptosis to occur. Above 200µM resveratrol, a shift from apoptosis to necrosis would 
cause a loss of intracellular Hsp72 such that resveratrol may not cause depletion of 
intracellular levels of Hsp72 in intact cells. 
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These findings are the first of their kind in leukaemia cell lines and the intracellular 
Hsp72 findings agree with related results presented by Cardile et al. (2003) and Putics 
et al. (2008). Cardile et al. (2003) reported that 50-100µM resveratrol induced Hsp70 
expression but 200µM caused no change in levels compared with control in human 
DU-145 prostate cancer cells, showing a similar pattern to the result presented here 
although with a higher range of resveratrol concentrations. Putics et al. (2008) reported 
that resveratrol activated HSF-1 and expression of Hsp70 in peripheral lymphocytes, 
monkey fibroblasts and human cervical cancer HeLa cells, but did not show that Hsp70 
levels were significantly reduced at higher concentrations of resveratrol although 
activation was seen to level off at 100-200µM resveratrol.  
 
The presented results are in contrast to findings by Chakraborty et al. (2008) who 
observed that 40µM resveratrol reduced Hsp70 levels over 24-72 hours in K562 
leukaemia cells with corresponding increases in apoptosis. This might imply that K562 
cells could be more sensitive to resveratrol. However, Ferry-Dumazet et al. (2002) 
observed that K562 cells were more resistant to the anti-proliferative effect of 
resveratrol than Jurkat and U937 cells, but would also undergo apoptosis. This research 
group also showed that resveratrol has different effects on cell cycle changes and 
cyclins in different leukaemia cell lines highlighting the complex cell dependent 
alterations induced by resveratrol. 
 
Studies investigating the effect of resveratrol on surface expression of Hsp72 were not 
found in literature searches accompanying this study, and thus the results presented are 
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believed to be so for the first time. Resveratrol caused a dose-dependent increase in 
surface levels of Hsp72. The finding that resveratrol increased Hsp72 at all 
concentrations used could indicate an induction of Hsp72 at lower, non-lethal 
concentrations (as observed by Putics et al., 2008 in other cell lines) and a movement 
of newly made proteins to the cell membrane, possibly to act as danger signals to the 
extracellular environment whilst elevated intracellular levels protect the cell. The level 
of surface Hsp72 levelled off at 100µM resveratrol when relative risk of apoptosis was 
high and the further increase at 200µM may reflect the shift to necrosis that is likely to 
occur at this concentration and thus, leakage of intracellular proteins. A shift from 
intracellular to extracellular Hsp72 at intermediate resveratrol concentrations may 
indicate a shift in danger management from cytoprotection to extracellular signalling. 
 
It is interesting that the induced expression of Hsp72 is not contained to intracellular 
protection purposes but is transported to the cell surface where it may play a role in 
stimulating the innate immune system. Furthermore, the findings indicating that 
intracellular Hsp72 levels may be protective of apoptosis suggest that resveratrol-
induced apoptosis may be more effective if Hsp72 levels were depressed. Hence, Hsp 





4.4. Manipulation of intracellular levels of Hsp72 may affect sensitivity 
of leukaemia cells to resveratrol-induced cell death 
 
In this study, increasing intracellular Hsp72 expression with a mild heat shock prior to 
resveratrol treatment caused a slight but significant increase in resistance of Jurkat and 
U937 cells to resveratrol-induced cell death. Significant results were seen at 50-100µM 
resveratrol with the caspase-3 assay only in Jurkat cells, and at 25 and 100µM with the 
PI assay only in U937 cells. Although a similar trend was seen in the PI assay for 
Jurkat cells and caspase-3 assay in U937 cells, the results were not significant, 
indicating that any changes were relatively small and thus difficult to obtain statistical 
significance for. It is possible that the change in sensitivity may have been more 
apparent at an earlier time point than 24 hours. However, statistical significance was 
achieved providing a novel finding that indicates that elevating Hsp72 levels does 
increase the resistance of Jurkat and U937 cells to resveratrol-induced cell death. 
Whilst Putics et al. (2008) showed that resveratrol synergized with mild-moderate heat 
shock, conferring enhanced cytoprotection against severe heat stress it is shown here 
that this effect extends to cytoprotection against resveratrol itself.  
 
Lowering intracellular Hsp72 expression by treatment with ethanol prior to resveratrol 
treatment was insufficient to increase sensitivity to resveratrol-induced cell death. 
However, there are several limitations to the experiment that may discredit the validity 
of this negative result, and the possibility that a true positive effect exists should not be 
dismissed. The limitations include that ethanol treatment is not a validated method to 
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depress Hsp72, the experimental procedure included steps that may have induced 
Hsp72 expression after ethanol treatment, and the experiments was only conducted 
once due to time restrictions and repeating the experiment to generate sufficient n 
numbers and improve statistical power would improve validity. Whilst results are 
presented demonstrating that 1.25% ethanol caused a significant reduction of 
intracellular Hsp72 after 2 hours incubation, the many steps in the experimental 
procedure after this initial incubation until resveratrol treatment was commenced (e.g. 
centrifugation, washing and re-suspending of cells causing possible mechanical stress 
and changes in temperature, although conducted with as much care and speed as 
possible) could have affected Hsp72 induction and uncoupled the effect of alcohol 
treatment. In addition, cells were incubated with resveratrol for 24 hours whereas the 
effect of depressed Hsp72 levels may only have lasted a shorter time period up until 
resveratrol was able to induce HSF-1 activity. Addressing the limitations to the 
experimental procedure to produce results with greater validity would be of great 
interest to elucidate whether Hsp72 reduction could increase the efficacy of resveratrol-
induced apoptosis. It would be especially interesting if low concentrations of 
resveratrol could be found to be effective as these may be the more relevant for in 
vivo/clinical work.  
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4.5. Further research and clinical relevance 
 
The presented findings confirm that resveratrol induces apoptosis and sensitises cells to 
TRAIL-induced apoptosis, and further reports that resveratrol acts synergistically with 
ethanol to enhance apoptosis in leukaemia cells in vitro. The mechanisms of these 
effects have yet to be fully elucidated, and warrant further investigation. Crucially, 
further research is required to assess whether these findings have clinical relevance. It 
is thus necessary to investigate what concentrations of resveratrol can be achieved in 
vivo and what concentrations are needed for therapeutic efficacy. Included in this, the 
toxicity profile and bioavailability need to be elucidated.  
 
Studies investigating the bioavailability of resveratrol have so far suggested that it is 
rapidly metabolised into its conjugates in the human body, and that these should 
therefore be considered in future studies (Wenzel and Somoza, 2005). It is thus 
necessary to characterize the therapeutic potential and efficacy of the conjugates and 
whether they have potential in anticancer therapy and if not, if it is possible to achieve 
suitable concentrations of unmodified resveratrol for clinical efficacy. Quercetin, a 
polyphenol found in many similar dietary sources as resveratrol, has been shown to 
increase the bioavailability of resveratrol by inhibiting relevant enzymes and thus is 
worthwhile further investigation (De Santi et al., 2000). 
 
Due to the predicted difficulty of achieving efficacious concentrations of resveratrol in 
vivo, research investigating further methods to enhance its efficacy is of interest. For 
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example, other dietary polyphenols may synergize with resveratrol and be potentially 
less toxic than ethanol. Quercetin has been shown to cause lipid raft aggregation and 
sensitise cells to TRAIL-induced apoptosis as well as increasing the bioavailability of 
resveratrol (Psahoulia et al., 2007). Curcumin is another polyphenol with promising 
anticancer and anti-inflammatory activity that may be worth testing in combination 
with resveratrol. Interestingly, Hsp70 modulation has recently been shown to change 
the sensitivity of colon cancer cells to curcumin-induced apopotis (Rashmi et al., 
2004). Crucially, the potential of Hsp72 manipulation to modulate efficacy of 
resveratrol was highlighted in this study. 
 
The findings present several questions regarding the involvement of Hsp70 in the 
mechanisms that resveratrol exhibits. Low concentrations of resveratrol that induce 
Hsp72 expression have been shown to be cytoprotective (Chan and Chang, 2006) 
whilst higher concentrations that fail to stimulate Hsp72 expression are cytotoxic, 
suggesting that Hsp induction could be the link between the cytoprotective and 
cytotoxic effects of resveratrol. Further investigation into this area may develop our 
understanding of resveratrol and Hsps and how they may be used for clinical benefit. 
For example, by modulating Hsp72 would it be possible to augment and control the 
cyto-protective/toxic effect of resveratrol? It would also be interesting to investigate 
whether the enhanced surface level expression of Hsp72 induced by resveratrol could 
activate the innate immune system in situ resulting in enhanced elimination of cancer 
cells (and override the anti-apoptotic effect conferred by increased intracellular 
Hsp72). If so, resveratrol may prove more efficacious in situ than in vitro and Hsp 
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therapy to reduce intracellular Hsp72 and increase surface Hsp72 levels would appear 
promising in combination anticancer therapy.  
 
Although pharmacological levels of the compounds have been discussed in this study, 
it would be of further interest to investigate whether oral consumption of dietary 
sources containing synergistic compounds (e.g. resveratrol, quercetin and ethanol in 
red wine) could be used to sensitise cancer cells in situ to anticancer therapy. I.e. could 








• Resveratrol induces cell death in the lymphoid and myeloid leukaemia cell lines 
Jurkat and U937. 
• Induced cell death is in the form of apoptosis at lower concentrations, and 
necrosis at higher concentrations, of resveratrol. 
• Resveratrol sensitises the leukaemia cell lines to TRAIL-induced apoptosis and 
displays a synergistic effect with ethanol on apoptosis induction. 
• Resveratrol, ethanol and TRAIL act synergistically in induction of apoptosis and 
cell death. Combination treatment with all three compounds induces a highly 
efficacious apoptosis at a lower concentration of resveratrol than achieved with 
single or double treatments, but also shows a greater potential toxicity by 
transition from apoptosis to necrosis occurring at lower concentrations of 
resveratrol. 
• Hsp72 expression is induced by low concentrations of resveratrol that are not 
effective at inducing apoptosis, revealed by a rise in intracellular and extracellular 
Hsp72 levels. Intracellular Hsp72 levels remain unchanged or reduced by higher 
concentrations of resvertrol that are able to induce significant apoptosis, whilst 
surface Hsp72 is further increased at these concentrations.  
• Increasing intracellular Hsp72 levels with a mild heat shock confers cells with 
increased resistance to resveratrol-induced apoptosis/cell death. 
• It was not possible to show that decreasing intracellular Hsp72 levels with ethanol 
sensitise cell to resveratrol-induced apooptis. However, since the experimental 
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procedure was flawed, the validity of the results is questioned and further 
investigation believed worthwhile. 
• Further research should consider how resveratrol treatment may gain clinical 
relevance by investigating how therapeutic concentrations may be achieved in 
vivo, whether other compounds with synergizing effects may benefit therapy, 
consider the impact of Hsp72 modulation, and whether pharmacological levels are 
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